Appeal letter generator
Runs in your browser. What you enter stays on your device.
How this works
Fill in the form and the generator writes a plain business letter: who you are, your plan, the medicine, the FDA-approved use that applies, what the plan said and what you've already tried. It adds a link to the medicine's FDA label. It ends by asking the plan for its exact criteria, and for the next appeal step if the answer is no.
- Anything you leave empty stays in the letter in square brackets. Nothing is made up for you.
- The approved-use wording comes from the FDA label. We do not write it.
- Print it, copy it, or download it as an .rtf file to edit in Word or Google Docs.
This is a starting point. It isn't legal advice, and it doesn't replace the medical notes your prescriber sends.
FDA-approved uses by medicine
A summary of section 1 of each label. Your coverage request should match one of these uses.
| Medicine | Approved uses on the label | Label version |
|---|---|---|
| Zepbound (tirzepatide) | reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with at least one weight-related comorbid condition; moderate to severe obstructive sleep apnea (OSA) in adults with obesity | Revised: 8/2026 (DailyMed version 40) |
| Mounjaro (tirzepatide) | adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events | Revised: 8/2026 (DailyMed version 40) |
| Wegovy (semaglutide) | Reduce the risk of major adverse cardiovascular events in adults with established CV disease and either obesity or overweight (injection and tablets); Reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity (injection); Reduce excess body weight and maintain weight reduction long term in adults with overweight and at least one weight-related comorbid condition (injection and tablets); Reduce excess body weight and maintain weight reduction long term in adults with obesity (tablets); Treatment of noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3) in adults, under accelerated approval (injection) | Revised: 6/2026 (DailyMed version 19) |
| Ozempic (semaglutide) | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (injection and tablets); Reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease (injection); Reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events (tablets); Reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease (injection) | Revised: 5/2026 (DailyMed version 20) |
| Foundayo (orforglipron) | reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with at least one weight-related comorbid condition | Revised: 7/2026 (DailyMed version 10) |
| Rybelsus (semaglutide) | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; Reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events | Revised: 1/2026 (DailyMed version 14) |
| Saxenda (liraglutide) | Reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity; Reduce excess body weight and maintain weight reduction long term in adults with overweight in the presence of at least one weight-related comorbid condition | Revised: 6/2026 (DailyMed version 22) |
| Trulicity (dulaglutide) | adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors | Revised: 3/2026 (DailyMed version 62) |
Frequently asked questions
Is anything I type saved or sent anywhere?
No. The letter is put together in your browser as you type. Nothing is uploaded, saved on our servers or added to a share link, and it is gone when you close the page. Copy or download the letter before you leave.
What is the difference between a prior authorization, an appeal and a formulary exception?
A prior authorization asks the plan to approve the medicine before it will pay. An appeal asks the plan to reverse a decision it has already made. A formulary exception asks the plan to cover a medicine that isn't on its list of covered drugs (the formulary), or to drop a restriction on it. The letter's wording changes with the type you pick.
Who should sign the letter?
You or your prescriber can write to the plan, and the generator words the letter for whoever you pick. Plans usually want medical details from the prescriber, so a letter from you works best when it goes in with your prescriber’s notes or a letter of medical necessity.
Where does the "FDA-approved use" wording come from?
It comes from the Indications and Usage section of the current FDA prescribing information for the medicine you pick. The letter links to that label. Choose the use your prescriber is actually treating. The generator won't add one for you.
Can I edit the letter afterwards?
Yes. Paste it into an email or a document, or download the .rtf file, which opens in Microsoft Word, Google Docs and Apple Pages. Anything you left blank shows in square brackets, so it is easy to find.
Does a letter guarantee coverage?
No. Each plan decides by its own written criteria. If it says no, ask the plan in writing which criteria you did not meet, and for the steps and deadline for the next level of appeal. The letter already asks for both.
Sources (8)
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
